Announcement: Aurelia Bioscience has been acquired by Charnwood Molecular.

Share this

Chief Commercial Officer, Mark Chadwick, provided context to the shift in the outsourcing of drug discovery.

The article goes on to look at the significant role CROs and CDMOs play and the advantages they bring.

Mark commented:

The scale and scope of outsourcing has changed markedly. At the start of my career [in the early 2000s], I worked for a company called BioFocus (now Charles River) and drug discovery outsourcing was in its infancy. Now it is a global industry.

Read the full article here.